The CSO at Aptamer group spoke recently in an interview with BioPharma APAC about Neuro-Bio’s ongoing partnership in which to develop Optimer binders to enable a lateral flow test for the early detection of Alzheimer’s disease. He also covered how a move away from traditional antibodies to more tuneable binders like Optimer technology is enabling improved diagnostic accuracy and development and how post-pandemic Optimer is helping side-step global logistical challenges.
We are grateful for Aptamer Group and being able to work together to try and help millions of people globally suffering from this cruel disease.